TDMS Study 96022-02 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) DATE: 04/27/04
EXPERIMENT: 96022 TEST: 02 TIME: 14:16:19
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: NO1-ES-75411 ROUTE: GAVAGE NTP C#: C96022
PATHOLOGIST: MISSING CAS: TEFPCBMIX
------------------------------------------------------------------------------------------------------------------------------------
CONTROL & TREATED GRPS. FINAL#1
REASONS FOR REMOVAL: 25018 Dosing Accident
25019 Moribund Sacrifice
25020 Natural Death
25021 Terminal Sacrifice
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE 001 0 NG / 0 UG
INCLUDE 002 80 NG /10 UG
INCLUDE 003 240 NG /30 UG
INCLUDE 004 800 NG /100 UG
INCLUDE 005 2400 NG/300 UG
INCLUDE 006 4000 NG/500 UG
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) DATE: 04/27/04
EXPERIMENT: 96022 TEST: 02 TIME: 14:16:19
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1-ES-75411 ROUTE: GAVAGE NTP C#: C96022
PATHOLOGIST: MISSING CAS: TEFPCBMIX
Rats(SPRAGUE-DAWLEY)
-----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE
BASED ON NUMBER OF TISSUES EXAMINED. IN OTHER TISSUES/ORGANS RATES
ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.
---------------
Adrenal Cortex
Adrenal Medulla
Brain
Clitoral/Preputial Gland
Heart
Islets, Pancreatic
Kidney
Liver
Lung
Ovary
Pancreas
Pituitary Gland
Thymus
Thyroid Gland
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) DATE: 04/27/04
EXPERIMENT: 96022 TEST: 02 TIME: 14:16:19
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1-ES-75411 ROUTE: GAVAGE NTP C#: C96022
PATHOLOGIST: MISSING CAS: TEFPCBMIX
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF TEF EVALUATION (PCB MIXTURE;PCB 126/P
===============================================================
Female Rats
------------
Organ Morphology
----- ----------
Adrenal Medulla Pheochromocytoma Benign
Pheochromocytoma: Benign, Complex, Malignant, NOS
Liver Cholangiocarcinoma
Hepatocellular Adenoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung Cystic Keratinizing Epithelioma
Mammary Gland Carcinoma
Carcinoma or Adenoma
Fibroadenoma
Fibroma, Fibroadenoma or Adenoma
Fibroma, Fibroadenoma, Carcinoma, or Adenoma
Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma
Carcinoma or Adenoma
Thyroid Gland: C-Cell Adenoma
Carcinoma
Carcinoma or Adenoma
Thyroid Gland: Follicular Cell Adenoma
Carcinoma or Adenoma
Uterus Polyp Stromal
All Organs Benign Tumors
Malignant Tumors
Malignant and Benign Tumors
===============================================================
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 1
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Benign |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 3/53 (6%) 3/51 (6%) 2/53 (4%) 0/53 (0%) 1/53 (2%) 0/64 (0%) |
|POLY-3 RATE (b) | 3/41.89 3/32.84 2/37.79 0/36.73 1/24.57 0/9.22 |
|POLY-3 PERCENT (g) | 7.2% 9.1% 5.3% 0.0% 4.1% 0.0% |
|TERMINAL (d) | 3/27 (11%) 2/17 (12%) 2/24 (8%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 659 726 (T) --- 520 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.618 P=0.447 P=0.555N P=0.240N P=0.433 P=1.000N |
|POLY 3 | P=0.187N P=0.546 P=0.547N P=0.143N P=0.508N P=0.484N |
|POLY 1.5 | P=0.126N P=0.578 P=0.530N P=0.134N P=0.415N P=0.307N |
|POLY 6 | P=0.214N P=0.515 P=0.564N P=0.159N P=0.637N P=0.605N |
|LOGISTIC REGRESSION| P=0.401N P=0.481 P=0.555N (e) P=0.663N (e) |
|COCH-ARM / FISHERS | P=0.034N* P=0.642 P=0.500N P=0.121N P=0.309N P=0.090N |
|ORDER RESTRICTED | P=0.496N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma: Benign, Complex, Malignant, NOS |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 3/53 (6%) 3/51 (6%) 3/53 (6%) 0/53 (0%) 1/53 (2%) 0/64 (0%) |
|POLY-3 RATE (b) | 3/41.89 3/32.84 3/38.61 0/36.73 1/24.57 0/9.22 |
|POLY-3 PERCENT (g) | 7.2% 9.1% 7.8% 0.0% 4.1% 0.0% |
|TERMINAL (d) | 3/27 (11%) 2/17 (12%) 2/24 (8%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 659 408 --- 520 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.608N P=0.447 P=0.619 P=0.240N P=0.433 P=1.000N |
|POLY 3 | P=0.165N P=0.546 P=0.625 P=0.143N P=0.508N P=0.484N |
|POLY 1.5 | P=0.104N P=0.578 P=0.639 P=0.134N P=0.415N P=0.307N |
|POLY 6 | P=0.202N P=0.515 P=0.611 P=0.159N P=0.637N P=0.605N |
|LOGISTIC REGRESSION| P=0.158N P=0.481 P=0.630 (e) P=0.663N (e) |
|COCH-ARM / FISHERS | P=0.025N* P=0.642 P=0.661N P=0.121N P=0.309N P=0.090N |
|ORDER RESTRICTED | P=0.512N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 2
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 2/42.25 0/32.58 0/37.79 0/36.73 0/23.94 0/9.28 |
|POLY-3 PERCENT (g) | 4.7% 0.0% 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 649 --- --- --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.543N P=0.336N P=0.277N P=0.304N P=0.692N P=1.000 |
|POLY 3 | P=0.233N P=0.299N P=0.262N P=0.269N P=0.379N P=0.564N |
|POLY 1.5 | P=0.238N P=0.281N P=0.253N P=0.257N P=0.311N P=0.424N |
|POLY 6 | P=0.188N P=0.318N P=0.273N P=0.290N P=0.482N P=0.651N |
|LOGISTIC REGRESSION| P=0.354N P=0.288N P=0.255N P=0.262N P=0.447N P=0.862N |
|COCH-ARM / FISHERS | P=0.188N P=0.257N P=0.248N P=0.248N P=0.248N P=0.200N |
|ORDER RESTRICTED | P=0.413N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Cholangiocarcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 5/53 (9%) 19/53 (36%) 28/53 (53%) 12/65 (18%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 5/37.79 19/39.63 28/35.01 12/17.32 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 13.2% 47.9% 80.0% 69.3% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 5/24 (21%) 6/15 (40%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- 726 (T) 567 450 294 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.022 * P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** (e) P=0.022 * P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.025 * P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** (e) P=0.019 * P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P=0.022 * P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.028 * P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 3
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 1/51 (2%) 0/53 (0%) 4/53 (8%) 17/53 (32%) 5/65 (8%) |
|POLY-3 RATE (b) | 2/41.89 1/32.84 0/37.79 4/37.67 17/30.45 5/13.19 |
|POLY-3 PERCENT (g) | 4.8% 3.1% 0.0% 10.6% 55.8% 37.9% |
|TERMINAL (d) | 2/27 (7%) 0/17 (0%) 0/24 (0%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 659 --- 541 474 245 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.645N P=0.264N P=0.164 P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.584N P=0.260N P=0.288 P<0.001 ** P=0.021 * |
|POLY 1.5 | P<0.001 ** P=0.562N P=0.252N P=0.304 P<0.001 ** P=0.061 |
|POLY 6 | P<0.001 ** P=0.604N P=0.269N P=0.262 P<0.001 ** P=0.010 * |
|LOGISTIC REGRESSION| P<0.001 ** P=0.616N (e) P=0.279 P<0.001 ** P=0.187 |
|COCH-ARM / FISHERS | P<0.001 ** P=0.515N P=0.248N P=0.339 P<0.001 ** P=0.312 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 1/51 (2%) 0/53 (0%) 4/53 (8%) 17/53 (32%) 5/65 (8%) |
|POLY-3 RATE (b) | 2/41.89 1/32.84 0/37.79 4/37.67 17/30.45 5/13.19 |
|POLY-3 PERCENT (g) | 4.8% 3.1% 0.0% 10.6% 55.8% 37.9% |
|TERMINAL (d) | 2/27 (7%) 0/17 (0%) 0/24 (0%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 659 --- 541 474 245 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.645N P=0.264N P=0.164 P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.584N P=0.260N P=0.288 P<0.001 ** P=0.021 * |
|POLY 1.5 | P<0.001 ** P=0.562N P=0.252N P=0.304 P<0.001 ** P=0.061 |
|POLY 6 | P<0.001 ** P=0.604N P=0.269N P=0.262 P<0.001 ** P=0.010 * |
|LOGISTIC REGRESSION| P<0.001 ** P=0.616N (e) P=0.279 P<0.001 ** P=0.187 |
|COCH-ARM / FISHERS | P<0.001 ** P=0.515N P=0.248N P=0.339 P<0.001 ** P=0.312 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 4
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, |
| or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 1/51 (2%) 0/53 (0%) 4/53 (8%) 17/53 (32%) 5/65 (8%) |
|POLY-3 RATE (b) | 2/41.89 1/32.84 0/37.79 4/37.67 17/30.45 5/13.19 |
|POLY-3 PERCENT (g) | 4.8% 3.1% 0.0% 10.6% 55.8% 37.9% |
|TERMINAL (d) | 2/27 (7%) 0/17 (0%) 0/24 (0%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 659 --- 541 474 245 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.645N P=0.264N P=0.164 P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.584N P=0.260N P=0.288 P<0.001 ** P=0.021 * |
|POLY 1.5 | P<0.001 ** P=0.562N P=0.252N P=0.304 P<0.001 ** P=0.061 |
|POLY 6 | P<0.001 ** P=0.604N P=0.269N P=0.262 P<0.001 ** P=0.010 * |
|LOGISTIC REGRESSION| P<0.001 ** P=0.616N (e) P=0.279 P<0.001 ** P=0.187 |
|COCH-ARM / FISHERS | P<0.001 ** P=0.515N P=0.248N P=0.339 P<0.001 ** P=0.312 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lung |
| Cystic Keratinizing Epithelioma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 20/53 (38%) 49/53 (92%) 41/66 (62%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 20/38.88 49/50.16 41/42.28 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 51.4% 97.7% 97.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 9/15 (60%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 594 267 260 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** (e) (e) P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) (e) P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** (e) (e) P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) (e) P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) (e) P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 5
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 2/53 (4%) 1/51 (2%) 0/53 (0%) 0/53 (0%) 0/53 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 2/42.41 1/33.21 0/37.79 0/36.73 0/23.94 0/9.33 |
|POLY-3 PERCENT (g) | 4.7% 3.0% 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 567 525 --- --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.318N P=0.614N P=0.266N P=0.318N P=0.638N P=0.987N |
|POLY 3 | P=0.176N P=0.584N P=0.263N P=0.270N P=0.380N P=0.564N |
|POLY 1.5 | P=0.170N P=0.562N P=0.253N P=0.258N P=0.311N P=0.423N |
|POLY 6 | P=0.153N P=0.606N P=0.274N P=0.291N P=0.482N P=0.650N |
|LOGISTIC REGRESSION| P=0.105N P=0.494N P=0.239N P=0.241N P=0.320N P=0.671N |
|COCH-ARM / FISHERS | P=0.112N P=0.515N P=0.248N P=0.248N P=0.248N P=0.196N |
|ORDER RESTRICTED | P=0.492N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 5/53 (9%) 1/51 (2%) 4/53 (8%) 0/53 (0%) 0/53 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 5/42.77 1/33.53 4/39.16 0/36.73 0/23.94 0/9.33 |
|POLY-3 PERCENT (g) | 11.7% 3.0% 10.2% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 4/27 (15%) 0/17 (0%) 2/24 (8%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 362 275 426 --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.096N P=0.197N P=0.555N P=0.087N P=0.512N P=0.642N |
|POLY 3 | P=0.030N* P=0.167N P=0.556N P=0.045N* P=0.120N P=0.382N |
|POLY 1.5 | P=0.021N* P=0.147N P=0.536N P=0.040N* P=0.068N P=0.170N |
|POLY 6 | P=0.037N* P=0.188N P=0.572N P=0.054N P=0.238N P=0.551N |
|LOGISTIC REGRESSION| P=0.003N** P=0.080N P=0.489N P=0.036N* P=0.065N P=0.255N |
|COCH-ARM / FISHERS | P=0.007N** P=0.112N P=0.500N P=0.028N* P=0.028N* P=0.016N* |
|ORDER RESTRICTED | P=0.352N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 6
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 6/53 (11%) 2/51 (4%) 4/53 (8%) 0/53 (0%) 0/53 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 6/43.29 2/34.15 4/39.16 0/36.73 0/23.94 0/9.33 |
|POLY-3 PERCENT (g) | 13.9% 5.9% 10.2% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 4/27 (15%) 0/17 (0%) 2/24 (8%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 362 275 426 --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.056N P=0.264N P=0.430N P=0.052N P=0.322N P=0.598N |
|POLY 3 | P=0.016N* P=0.222N P=0.433N P=0.025N* P=0.085N P=0.346N |
|POLY 1.5 | P=0.011N* P=0.196N P=0.411N P=0.022N* P=0.042N* P=0.129N |
|POLY 6 | P=0.020N* P=0.249N P=0.455N P=0.033N* P=0.197N P=0.533N |
|LOGISTIC REGRESSION| P<0.001N** P=0.093N P=0.349N P=0.017N* P=0.025N* P=0.106N |
|COCH-ARM / FISHERS | P=0.003N** P=0.148N P=0.371N P=0.013N* P=0.013N* P=0.007N** |
|ORDER RESTRICTED | P=0.313N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroadenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 42/53 (79%) 38/51 (75%) 36/53 (68%) 17/53 (32%) 4/53 (8%) 6/66 (9%) |
|POLY-3 RATE (b) | 42/51.89 38/44.64 36/47.82 17/40.43 4/26.10 6/14.37 |
|POLY-3 PERCENT (g) | 81.0% 85.1% 75.3% 42.0% 15.3% 41.8% |
|TERMINAL (d) | 19/27 (70%) 13/17 (77%) 16/24 (67%) 7/15 (47%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 347 426 261 479 222 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.206N P=0.107 P=0.493N P=0.019N* P=0.082N P=0.115 |
|POLY 3 | P<0.001N** P=0.389 P=0.324N P<0.001N** P<0.001N** P=0.016N* |
|POLY 1.5 | P<0.001N** P=0.480 P=0.257N P<0.001N** P<0.001N** P<0.001N** |
|POLY 6 | P<0.001N** P=0.339 P=0.398N P<0.001N** P<0.001N** P=0.454N |
|LOGISTIC REGRESSION| P<0.001N** P=0.497N P=0.133N P<0.001N** P<0.001N** P<0.001N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.367N P=0.135N P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 7
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 42/53 (79%) 39/51 (76%) 36/53 (68%) 17/53 (32%) 4/53 (8%) 6/66 (9%) |
|POLY-3 RATE (b) | 42/51.89 39/45.26 36/47.82 17/40.43 4/26.10 6/14.37 |
|POLY-3 PERCENT (g) | 81.0% 86.2% 75.3% 42.0% 15.3% 41.8% |
|TERMINAL (d) | 19/27 (70%) 13/17 (77%) 16/24 (67%) 7/15 (47%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 347 426 261 479 222 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.188N P=0.083 P=0.493N P=0.019N* P=0.082N P=0.115 |
|POLY 3 | P<0.001N** P=0.334 P=0.324N P<0.001N** P<0.001N** P=0.016N* |
|POLY 1.5 | P<0.001N** P=0.402 P=0.257N P<0.001N** P<0.001N** P<0.001N** |
|POLY 6 | P<0.001N** P=0.307 P=0.398N P<0.001N** P<0.001N** P=0.454N |
|LOGISTIC REGRESSION| P<0.001N** P=0.581N P=0.133N P<0.001N** P<0.001N** P<0.001N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.458N P=0.135N P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma, Carcinoma, or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 42/53 (79%) 40/51 (78%) 37/53 (70%) 17/53 (32%) 4/53 (8%) 6/66 (9%) |
|POLY-3 RATE (b) | 42/51.89 40/46.21 37/48.39 17/40.43 4/26.10 6/14.37 |
|POLY-3 PERCENT (g) | 81.0% 86.6% 76.5% 42.0% 15.3% 41.8% |
|TERMINAL (d) | 19/27 (70%) 13/17 (77%) 16/24 (67%) 7/15 (47%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 275 426 261 479 222 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.149N P=0.065 P=0.550N P=0.019N* P=0.082N P=0.115 |
|POLY 3 | P<0.001N** P=0.312 P=0.377N P<0.001N** P<0.001N** P=0.016N* |
|POLY 1.5 | P<0.001N** P=0.362 P=0.318N P<0.001N** P<0.001N** P<0.001N** |
|POLY 6 | P<0.001N** P=0.291 P=0.435N P<0.001N** P<0.001N** P=0.454N |
|LOGISTIC REGRESSION| P<0.001N** P=0.573 P=0.178N P<0.001N** P<0.001N** P<0.001N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.555N P=0.186N P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 8
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Oral Cavity (Oral Mucosa, Tongue, Pharynx, Tooth, Gingiva) |
| Squamous Cell Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 1/53 (2%) 1/51 (2%) 2/53 (4%) 4/53 (8%) 0/53 (0%) 1/66 (2%) |
|POLY-3 RATE (b) | 1/42.04 1/32.86 2/38.20 4/37.76 0/23.94 1/10.03 |
|POLY-3 PERCENT (g) | 2.4% 3.0% 5.2% 10.6% 0.0% 10.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 1/24 (4%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 687 651 608 594 --- 482 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.063 P=0.674 P=0.445 P=0.105 P=0.970N P=0.186 |
|POLY 3 | P=0.511 P=0.703 P=0.467 P=0.146 P=0.605N P=0.447 |
|POLY 1.5 | P=0.495N P=0.719 P=0.479 P=0.157 P=0.559N P=0.583 |
|POLY 6 | P=0.267 P=0.687 P=0.455 P=0.131 P=0.663N P=0.363 |
|LOGISTIC REGRESSION| P=0.587 P=0.720 P=0.474 P=0.158 P=0.760N P=0.663 |
|COCH-ARM / FISHERS | P=0.205N P=0.743 P=0.500 P=0.181 P=0.500N P=0.694N |
|ORDER RESTRICTED | P=0.487 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Oral Cavity (Oral Mucosa, Tongue, Pharynx, Tooth, Gingiva) |
| Squamous Cell Carcinoma, Papilloma Squamous, or Papilloma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 1/53 (2%) 1/51 (2%) 2/53 (4%) 4/53 (8%) 0/53 (0%) 1/66 (2%) |
|POLY-3 RATE (b) | 1/42.04 1/32.86 2/38.20 4/37.76 0/23.94 1/10.03 |
|POLY-3 PERCENT (g) | 2.4% 3.0% 5.2% 10.6% 0.0% 10.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 1/24 (4%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 687 651 608 594 --- 482 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.063 P=0.674 P=0.445 P=0.105 P=0.970N P=0.186 |
|POLY 3 | P=0.511 P=0.703 P=0.467 P=0.146 P=0.605N P=0.447 |
|POLY 1.5 | P=0.495N P=0.719 P=0.479 P=0.157 P=0.559N P=0.583 |
|POLY 6 | P=0.267 P=0.687 P=0.455 P=0.131 P=0.663N P=0.363 |
|LOGISTIC REGRESSION| P=0.587 P=0.720 P=0.474 P=0.158 P=0.760N P=0.663 |
|COCH-ARM / FISHERS | P=0.205N P=0.743 P=0.500 P=0.181 P=0.500N P=0.694N |
|ORDER RESTRICTED | P=0.487 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 9
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Oral Mucosa |
| Squamous Cell Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 1/53 (2%) 1/51 (2%) 2/53 (4%) 4/53 (8%) 0/53 (0%) 1/66 (2%) |
|POLY-3 RATE (b) | 1/42.04 1/32.86 2/38.20 4/37.76 0/23.94 1/10.03 |
|POLY-3 PERCENT (g) | 2.4% 3.0% 5.2% 10.6% 0.0% 10.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 1/24 (4%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 687 651 608 594 --- 482 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.063 P=0.674 P=0.445 P=0.105 P=0.970N P=0.186 |
|POLY 3 | P=0.511 P=0.703 P=0.467 P=0.146 P=0.605N P=0.447 |
|POLY 1.5 | P=0.495N P=0.719 P=0.479 P=0.157 P=0.559N P=0.583 |
|POLY 6 | P=0.267 P=0.687 P=0.455 P=0.131 P=0.663N P=0.363 |
|LOGISTIC REGRESSION| P=0.587 P=0.720 P=0.474 P=0.158 P=0.760N P=0.663 |
|COCH-ARM / FISHERS | P=0.205N P=0.743 P=0.500 P=0.181 P=0.500N P=0.694N |
|ORDER RESTRICTED | P=0.487 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pancreas |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 2/53 (4%) 0/53 (0%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 2/38.31 0/36.73 0/23.94 0/9.28 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 5.2% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 1/24 (4%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- 567 --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.702N (e) P=0.214 (e) (e) (e) |
|POLY 3 | P=0.467N (e) P=0.217 (e) (e) (e) |
|POLY 1.5 | P=0.396N (e) P=0.224 (e) (e) (e) |
|POLY 6 | P=0.523N (e) P=0.211 (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.399N (e) P=0.233 (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.253N (e) P=0.248 (e) (e) (e) |
|ORDER RESTRICTED | P=0.682 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 10
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 30/53 (57%) 11/51 (22%) 16/52 (31%) 10/53 (19%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 30/44.61 11/34.16 16/40.06 10/38.64 0/23.94 0/9.27 |
|POLY-3 PERCENT (g) | 67.3% 32.2% 39.9% 25.9% 0.0% 0.0% |
|TERMINAL (d) | 21/27 (78%) 6/17 (35%) 10/24 (42%) 4/15 (27%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 582 541 548 537 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.018N* P=0.026N* P=0.029N* P=0.020N* P=0.125N P=0.840N |
|POLY 3 | P<0.001N** P<0.001N** P=0.007N** P<0.001N** P<0.001N** P=0.008N** |
|POLY 1.5 | P<0.001N** P<0.001N** P=0.006N** P<0.001N** P<0.001N** P<0.001N** |
|POLY 6 | P<0.001N** P=0.002N** P=0.008N** P<0.001N** P<0.001N** P=0.260N |
|LOGISTIC REGRESSION| P<0.001N** P=0.003N** P=0.015N* P<0.001N** P<0.001N** P=0.172N |
|COCH-ARM / FISHERS | P<0.001N** P<0.001N** P=0.007N** P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P=0.008N** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 30/53 (57%) 11/51 (22%) 17/52 (33%) 10/53 (19%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 30/44.61 11/34.16 17/40.57 10/38.64 0/23.94 0/9.27 |
|POLY-3 PERCENT (g) | 67.3% 32.2% 41.9% 25.9% 0.0% 0.0% |
|TERMINAL (d) | 21/27 (78%) 6/17 (35%) 10/24 (42%) 4/15 (27%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 582 541 548 537 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.016N* P=0.026N* P=0.049N* P=0.020N* P=0.125N P=0.840N |
|POLY 3 | P<0.001N** P<0.001N** P=0.011N* P<0.001N** P<0.001N** P=0.008N** |
|POLY 1.5 | P<0.001N** P<0.001N** P=0.011N* P<0.001N** P<0.001N** P<0.001N** |
|POLY 6 | P<0.001N** P=0.002N** P=0.012N* P<0.001N** P<0.001N** P=0.260N |
|LOGISTIC REGRESSION| P<0.001N** P=0.003N** P=0.025N* P<0.001N** P<0.001N** P=0.172N |
|COCH-ARM / FISHERS | P<0.001N** P<0.001N** P=0.011N* P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P=0.008N** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 11
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Skin |
| Basal or Sq. Cell Carcinoma, Carcinoma, Basosq. Tumor |
| (M or B), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepitheliom |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 2/53 (4%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 0/53 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 2/41.89 0/32.58 0/37.79 0/36.73 0/23.94 0/9.33 |
|POLY-3 PERCENT (g) | 4.8% 0.0% 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 2/27 (7%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) --- --- --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.802N P=0.344N P=0.264N P=0.374N P=1.000N P=1.000N |
|POLY 3 | P=0.234N P=0.296N P=0.260N P=0.267N P=0.377N P=0.562N |
|POLY 1.5 | P=0.238N P=0.280N P=0.252N P=0.256N P=0.310N P=0.421N |
|POLY 6 | P=0.189N P=0.314N P=0.269N P=0.286N P=0.478N P=0.650N |
|LOGISTIC REGRESSION| P=0.802N (e) (e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.186N P=0.257N P=0.248N P=0.248N P=0.248N P=0.196N |
|ORDER RESTRICTED | P=0.408N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Skin |
| Fibroma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 1/53 (2%) 1/51 (2%) 1/53 (2%) 3/53 (6%) 0/53 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 1/41.89 1/32.90 1/37.88 3/36.99 0/23.94 0/9.33 |
|POLY-3 PERCENT (g) | 2.4% 3.0% 2.6% 8.1% 0.0% 0.0% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 0/24 (0%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 639 703 659 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.479 P=0.668 P=0.735 P=0.152 P=1.000N P=1.000N |
|POLY 3 | P=0.531N P=0.705 P=0.738 P=0.261 P=0.604N P=0.696N |
|POLY 1.5 | P=0.329N P=0.720 P=0.747 P=0.276 P=0.559N P=0.625N |
|POLY 6 | P=0.415 P=0.690 P=0.730 P=0.238 P=0.662N P=0.735N |
|LOGISTIC REGRESSION| P=0.646N P=0.708 P=0.730 P=0.204 (e) (e) |
|COCH-ARM / FISHERS | P=0.105N P=0.743 P=0.752N P=0.309 P=0.500N P=0.445N |
|ORDER RESTRICTED | P=0.635N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 12
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Skin |
| Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, |
| or Fibrous Histiocytoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 1/53 (2%) 1/51 (2%) 2/53 (4%) 3/53 (6%) 0/53 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 1/41.89 1/32.90 2/37.88 3/36.99 0/23.94 0/9.33 |
|POLY-3 PERCENT (g) | 2.4% 3.0% 5.3% 8.1% 0.0% 0.0% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 1/24 (4%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 639 703 659 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.477 P=0.668 P=0.460 P=0.152 P=1.000N P=1.000N |
|POLY 3 | P=0.467N P=0.705 P=0.465 P=0.261 P=0.604N P=0.696N |
|POLY 1.5 | P=0.271N P=0.720 P=0.478 P=0.276 P=0.559N P=0.625N |
|POLY 6 | P=0.460 P=0.690 P=0.453 P=0.238 P=0.662N P=0.735N |
|LOGISTIC REGRESSION| P=0.631N P=0.708 P=0.449 P=0.204 (e) (e) |
|COCH-ARM / FISHERS | P=0.075N P=0.743 P=0.500 P=0.309 P=0.500N P=0.445N |
|ORDER RESTRICTED | P=0.618N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 9/53 (17%) 5/51 (10%) 8/53 (15%) 8/52 (15%) 4/52 (8%) 1/66 (2%) |
|POLY-3 RATE (b) | 9/43.64 5/34.06 8/38.66 8/37.23 4/24.72 1/9.65 |
|POLY-3 PERCENT (g) | 20.6% 14.7% 20.7% 21.5% 16.2% 10.4% |
|TERMINAL (d) | 4/27 (15%) 1/17 (6%) 5/24 (21%) 5/15 (33%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 548 611 632 619 639 636 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.002 ** P=0.468N P=0.588 P=0.344 P=0.069 P=0.183 |
|POLY 3 | P=0.420N P=0.353N P=0.605 P=0.571 P=0.452N P=0.429N |
|POLY 1.5 | P=0.126N P=0.307N P=0.569N P=0.599N P=0.275N P=0.135N |
|POLY 6 | P=0.327 P=0.396N P=0.567 P=0.500 P=0.523 P=0.547 |
|LOGISTIC REGRESSION| P=0.484 P=0.292N P=0.582N P=0.587 P=0.614N P=0.586N |
|COCH-ARM / FISHERS | P=0.002N** P=0.217N P=0.500N P=0.517N P=0.125N P=0.003N** |
|ORDER RESTRICTED | P=0.589N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 13
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 4/53 (8%) 2/51 (4%) 2/53 (4%) 0/52 (0%) 0/52 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 4/42.04 2/32.58 2/37.79 0/36.44 0/23.93 0/9.33 |
|POLY-3 PERCENT (g) | 9.5% 6.1% 5.3% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 3/27 (11%) 2/17 (12%) 2/24 (8%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 688 726 (T) 726 (T) --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.290N P=0.554N P=0.391N P=0.152N P=0.965N P=1.000N |
|POLY 3 | P=0.044N* P=0.460N P=0.387N P=0.080N P=0.169N P=0.425N |
|POLY 1.5 | P=0.035N* P=0.425N P=0.368N P=0.074N P=0.110N P=0.223N |
|POLY 6 | P=0.045N* P=0.496N P=0.407N P=0.092N P=0.290N P=0.573N |
|LOGISTIC REGRESSION| P=0.204N P=0.530N P=0.403N P=0.112N P=0.572N P=0.994N |
|COCH-ARM / FISHERS | P=0.014N* P=0.358N P=0.339N P=0.061N P=0.061N P=0.037N* |
|ORDER RESTRICTED | P=0.401N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 13/53 (25%) 7/51 (14%) 9/53 (17%) 8/52 (15%) 4/52 (8%) 1/66 (2%) |
|POLY-3 RATE (b) | 13/43.79 7/34.06 9/38.66 8/37.23 4/24.72 1/9.65 |
|POLY-3 PERCENT (g) | 29.7% 20.6% 23.3% 21.5% 16.2% 10.4% |
|TERMINAL (d) | 7/27 (26%) 3/17 (18%) 6/24 (25%) 5/15 (33%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 548 611 632 619 639 636 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.008 ** P=0.407N P=0.357N P=0.557N P=0.081 P=0.183 |
|POLY 3 | P=0.141N P=0.256N P=0.341N P=0.277N P=0.181N P=0.298N |
|POLY 1.5 | P=0.024N* P=0.208N P=0.298N P=0.237N P=0.069N P=0.043N* |
|POLY 6 | P=0.396N P=0.305N P=0.387N P=0.350N P=0.461N P=0.594N |
|LOGISTIC REGRESSION| P=0.485N P=0.242N P=0.331N P=0.282N P=0.424N P=0.570N |
|COCH-ARM / FISHERS | P<0.001N** P=0.125N P=0.237N P=0.177N P=0.018N* P<0.001N** |
|ORDER RESTRICTED | P=0.385N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 14
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 2/53 (4%) 0/52 (0%) 2/52 (4%) 1/66 (2%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 2/38.13 0/36.44 2/24.61 1/10.09 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 5.3% 0.0% 8.1% 9.9% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 1/24 (4%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- 632 --- 565 452 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.209 (e) P=0.028 * P=0.261 |
|POLY 3 | P=0.072 (e) P=0.216 (e) P=0.143 P=0.307 |
|POLY 1.5 | P=0.117 (e) P=0.224 (e) P=0.179 P=0.377 |
|POLY 6 | P=0.056 (e) P=0.210 (e) P=0.105 P=0.268 |
|LOGISTIC REGRESSION| P=0.071 (e) P=0.218 (e) P=0.147 P=0.656 |
|COCH-ARM / FISHERS | P=0.316 (e) P=0.248 (e) P=0.243 P=0.555 |
|ORDER RESTRICTED | P=0.244 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 0/51 (0%) 2/53 (4%) 0/52 (0%) 3/52 (6%) 1/66 (2%) |
|POLY-3 RATE (b) | 1/41.89 0/32.58 2/38.13 0/36.44 3/25.10 1/10.09 |
|POLY-3 PERCENT (g) | 2.4% 0.0% 5.3% 0.0% 12.0% 9.9% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 1/24 (4%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) --- 632 --- 565 452 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.592N P=0.453 P=0.617N P=0.007 ** P=0.261 |
|POLY 3 | P=0.053 P=0.550N P=0.467 P=0.528N P=0.156 P=0.448 |
|POLY 1.5 | P=0.107 P=0.536N P=0.479 P=0.519N P=0.212 P=0.584 |
|POLY 6 | P=0.038 * P=0.563N P=0.457 P=0.542N P=0.098 P=0.364 |
|LOGISTIC REGRESSION| P=0.052 (e) P=0.458 (e) P=0.137 P=0.643 |
|COCH-ARM / FISHERS | P=0.373 P=0.510N P=0.500 P=0.505N P=0.302 P=0.694N |
|ORDER RESTRICTED | P=0.314 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 15
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 11/53 (21%) 6/51 (12%) 7/53 (13%) 8/53 (15%) 7/53 (13%) 3/66 (5%) |
|POLY-3 RATE (b) | 11/44.47 6/33.44 7/39.93 8/37.87 7/26.50 3/11.76 |
|POLY-3 PERCENT (g) | 24.7% 17.9% 17.5% 21.1% 26.4% 25.5% |
|TERMINAL (d) | 4/27 (15%) 4/17 (24%) 3/24 (13%) 5/15 (33%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 534 534 399 555 530 300 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.439N P=0.337N P=0.534 P=0.027 * P=0.040 * |
|POLY 3 | P=0.347 P=0.331N P=0.294N P=0.450N P=0.548 P=0.588 |
|POLY 1.5 | P=0.408N P=0.267N P=0.263N P=0.393N P=0.456N P=0.250N |
|POLY 6 | P=0.128 P=0.408N P=0.331N P=0.545N P=0.282 P=0.333 |
|LOGISTIC REGRESSION| P=0.521 P=0.256N P=0.222N P=0.379N P=0.580N P=0.264N |
|COCH-ARM / FISHERS | P=0.019N* P=0.165N P=0.219N P=0.307N P=0.219N P=0.007N** |
|ORDER RESTRICTED | P=0.687 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 53/53 (100%) 43/51 (84%) 47/53 (89%) 40/53 (75%) 51/53 (96%) 45/66 (68%) |
|POLY-3 RATE (b) | 53/53.00 43/45.66 47/50.14 40/45.86 51/51.18 45/45.91 |
|POLY-3 PERCENT (g) | 100.0% 94.2% 93.7% 87.2% 99.7% 98.0% |
|TERMINAL (d) | 27/27 (100%) 15/17 (88%) 22/24 (92%) 13/15 (87%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 347 399 261 267 222 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.187 P=0.542 P=0.346 P<0.001 ** P<0.001 ** |
|POLY 3 | P=0.136 P=0.099N P=0.074N P=0.003N** P=1.000N P=0.542N |
|POLY 1.5 | P=0.564 P=0.038N* P=0.045N* P<0.001N** P=0.872N P<0.001N** |
|POLY 6 | P=0.090 P=0.169N P=0.134N P=0.017N* P=1.000N P=1.000N |
|LOGISTIC REGRESSION| P=0.033 * P=0.028N* P=0.029N* P<0.001N** P=0.525N P=0.352N |
|COCH-ARM / FISHERS | P<0.001N** P=0.002N** P=0.013N* P<0.001N** P=0.248N P<0.001N** |
|ORDER RESTRICTED | P=0.091N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/27/04 EXPERIMENT: 96022 TEST: 02 Page 16
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 16/53 (30%) 13/51 (25%) 18/53 (34%) 22/53 (42%) 28/53 (53%) 14/66 (21%) |
|POLY-3 RATE (b) | 16/44.14 13/38.29 18/41.74 22/40.90 28/35.01 14/18.92 |
|POLY-3 PERCENT (g) | 36.3% 34.0% 43.1% 53.8% 80.0% 74.0% |
|TERMINAL (d) | 10/27 (37%) 3/17 (18%) 11/24 (46%) 6/15 (40%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 362 275 408 567 450 294 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.408 P=0.276 P=0.013 * P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.505N P=0.330 P=0.071 P<0.001 ** P=0.014 * |
|POLY 1.5 | P<0.001 ** P=0.473N P=0.358 P=0.089 P<0.001 ** P=0.151 |
|POLY 6 | P<0.001 ** P=0.528N P=0.307 P=0.057 P<0.001 ** P=0.002 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.397N P=0.343 P=0.069 P<0.001 ** P=0.002 ** |
|COCH-ARM / FISHERS | P=0.353N P=0.377N P=0.418 P=0.156 P=0.015 * P=0.182N |
|ORDER RESTRICTED | P=0.005 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # # |
|----------- | |
|OVERALL (a) | 53/53 (100%) 47/51 (92%) 51/53 (96%) 42/53 (79%) 51/53 (96%) 45/66 (68%) |
|POLY-3 RATE (b) | 53/53.00 47/48.14 51/52.00 42/46.43 51/51.18 45/45.91 |
|POLY-3 PERCENT (g) | 100.0% 97.6% 98.1% 90.5% 99.7% 98.0% |
|TERMINAL (d) | 27/27 (100%) 16/17 (94%) 23/24 (96%) 13/15 (87%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 275 399 261 267 222 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.071 P=0.321 P=0.246 P<0.001 ** P<0.001 ** |
|POLY 3 | P=0.472 P=0.424N P=0.496N P=0.013N* P=1.000N P=0.542N |
|POLY 1.5 | P=0.098N P=0.319N P=0.486N P=0.004N** P=0.872N P<0.001N** |
|POLY 6 | P=0.263 P=0.473N P=0.496N P=0.062N P=1.000N P=1.000N |
|LOGISTIC REGRESSION| P=0.370 P=0.229N P=0.341N P=0.002N** P=0.525N P=0.352N |
|COCH-ARM / FISHERS | P<0.001N** P=0.054N P=0.248N P<0.001N** P=0.248N P<0.001N** |
|ORDER RESTRICTED | P=0.114N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Number of tumor-bearing animals / Poly-3 number
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death.
Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fishers exact tests compare directly the overall incidence rates
For all tests a negative trend is indicated by N
(e) Value of Statistic cannot be computed.
(g) Poly-3 adjusted lifetime tumor incidence.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).